Madrigal Pharmaceuticals Inc. (MDGL) exhibits 41.0% gross margins and -29.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.2% implied options volatility.
Sustained 41.0% gross profitability converts into -31.3% operating margin and -29.7% ROIC, outpacing sector cost of capital.
ROIC: -29.7% // GM: 41.0%YoY revenue trajectory of +180.0% paired with -1.91% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +180.0% // FCF YLD: -1.91%Altman Z-Score of 7.65 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 7.65 // F-SCORE: 6/9Trading at 24.0x trailing P/E (24.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.2% implied move with a 0.78 put/call ratio around $423.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.78Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -30.1% net margins.
NET MARGIN: -30.1% // D/E: 0.56x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MDGL & activate live FRED threshold breach alerts.